In this second installment of MedPage Today's virtual roundtable series on pediatric low-grade glioma, moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, is joined once ...

MedPage Today brought together three expert leaders for a virtual roundtable discussion on pediatric low-grade glioma. Moderator Jason Fangusaro, MD, of Emory University School of Medicine in Atlanta, ...

Maximal resection of low-grade glioma shortly after diagnosis may lead to longer survival, according to research published in the Journal of Clinical Oncology. The findings of the University of ...

Pediatric gliomas are also known as childhood gliomas. They’re a type of tumor that can develop in a child’s central nervous system (CNS), including their brain or spinal cord. Gliomas are tumors that ...

Please provide your email address to receive an email when new articles are posted on . Two-thirds of patients with relapsed pediatric low-grade glioma treated with tovorafenib responded to therapy, ...

If your child has been diagnosed with a pediatric low-grade glioma (pLGG), you may be wondering where, exactly, you should go for medical care. For starters, you’ll want to look for a treatment center ...

Ojemda is the first FDA-approved systemic therapy for pediatric LGG patients with BRAF rearrangements, including fusions. The Food and Drug Administration (FDA) has granted accelerated approval to ...

Credit: Getty Images. This is the first FDA-approved systemic therapy for first-line treatment of pediatric patients with low-grade glioma with a BRAF V600E mutation. The Food and Drug Administration ...

Brain tumors have long been treated as rogue invaders: growing, spreading, and resisting treatment on their own. But new ...

For Brain Cancer Awareness Month, AJMC shares an interview with Day One Biopharmaceuticals CEO Jeremy Bender, PhD, MBA. Bender discussed the company's lead agent, tovorafenib, which has shown promise ...

Gomekli showed an 87% overall response rate in pediatric low-grade glioma with MAPK pathway activation, with a recommended dose of 3 mg/m2 twice daily. Common adverse effects included weight gain, ...